Systematic Review
Accepted on 04 Feb 2026
Meta-Analysis of Efficacy and Safety of Yttrium-90 Radioembolization (TARE) in the Treatment of Advanced Hepatocellular Carcinoma
in Radionuclide Therapy
Frontiers in Nuclear Medicine
- 136 views
Type at least 3 characters
25 articles
articles
Mini Review
Published on 05 Dec 2025
Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2025.1737443
- 2,090 views
Original Research
Published on 27 Nov 2024
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1480471
- 3,783 views
- 5 citations
Editorial
Published on 09 May 2024
Editorial: Women in radionuclide therapy: 2023
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1411878
- 1,632 views
Editorial
Published on 11 Apr 2024
Editorial: Bridging the gap to molecular imaging and theranostics
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1385097
- 2,525 views
- 1 citation
Review
Published on 04 Apr 2024
Immunological effects of radiopharmaceutical therapy
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2024.1331364
- 14,608 views
- 18 citations
Review
Published on 10 Jan 2024
The application of radionuclide therapy for breast cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1323514
- 8,485 views
- 4 citations
Original Research
Published on 06 Dec 2023
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1284558
- 2,995 views
- 7 citations
Review
Published on 25 Oct 2023
Emerging theragnostic radionuclide applications for hepatocellular carcinoma
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1210982
- 4,184 views
- 5 citations
Review
Published on 04 Aug 2023
Theranostics in breast cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1236565
- 11,918 views
- 16 citations
Case Report
Published on 03 Aug 2023
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1193880
- 2,399 views
- 3 citations
Review
Published on 27 Jul 2023
Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1224905
- 3,262 views
- 1 citation
Review
Published on 25 Jul 2023
Biodosimetry, can it find its way to the nuclear medicine clinic?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1209823
- 5,951 views
- 4 citations
Mini Review
Published on 23 Jun 2023
A brief overview of targeted radionuclide therapy trials in 2022
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1169650
- 8,265 views
- 9 citations
Original Research
Published on 15 May 2023
Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.964478
- 3,148 views
- 3 citations
Original Research
Published on 21 Mar 2023
Insights into handling and delivery of Y-90 radioembolization therapies
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1075782
- 5,746 views
- 2 citations
Case Report
Published on 23 Feb 2023
Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2023.1074948
- 6,590 views
- 4 citations
Case Report
Published on 17 Jan 2023
Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.1071022
- 2,988 views
- 4 citations
Review
Published on 09 Jan 2023
Radiometal chelators for infection diagnostics
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.1058388
- 10,215 views
- 9 citations
Original Research
Published on 22 Jul 2022
ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.934446
- 3,218 views
Perspective
Published on 03 May 2022
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.863101
- 5,525 views
- 6 citations
Case Report
Published on 15 Mar 2022
Anti-thyroglobulin Antibodies as a Possible Risk Factor for Graves' Disease After Radioiodine Treatment for Toxic Nodular Goiter: Case Report
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.858062
- 3,603 views
- 2 citations
Review
Published on 01 Feb 2022
Imaging Lymphoma With F-18 Fluorodeoxyglucose PET-CT: What Should Be Known About Normal Variants, Pitfalls, and Artifacts?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2021.826046
- 9,912 views
- 4 citations
Review
Published on 21 Jan 2022
Shared Decision Making for Radioiodine Therapy and the Actual Pattern of Care in Intermediate-Risk Differentiated Thyroid Carcinoma
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2021.797522
- 2,711 views
- 1 citation